|PDI is a leading health care commercialization company providing superior insight-driven, integrated multi-channel message delivery to established and emerging health care companies. The company is dedicated to enhancing engagement with health care practitioners and optimizing commercial investments for its clients by providing strategic flexibility, full product commercialization services, innovative multi-channel promotional solutions, and sales and marketing expertise.... More >>|
|11/12/13||PDI Reports Third Quarter 2013 Financial Results|
|PARSIPPANY, N.J., Nov. 12, 2013 /PRNewswire/ -- PDI, Inc. (Nasdaq: PDII), today reported financial and operational results for the third quarter ended September 30, 2013. Third quarter and subsequent financial and operational accomplishments include:
Revenues increased 8% to $34.3 million for the third quarter of 2013 and 25% to $114.4 million for the nine months of 2013 compared to the same periods last year
Adjusted EBITDA (a non-GAAP financial measure) of $(1.3) million for the 2013 th... |
|11/05/13||PDI, Inc. to Hold Third Quarter 2013 Financial Results Conference Call on Tuesday, November 12, 2013|
|PARSIPPANY, N.J., Nov. 5, 2013 /PRNewswire/ -- PDI, Inc. (Nasdaq: PDII) today announced that it will release its third quarter 2013 financial results on Tuesday, November 12, 2013 after the market close and host a conference call beginning at 5:00 pm Eastern time to discuss the results.
Tuesday, November 12, 2013
5:00 pm Eastern time
|10/30/13||PDI, Inc. Appoints Molecular Diagnostics Leader to Board of Directors|
|PARSIPPANY, N.J., Oct. 30, 2013 /PRNewswire/ -- PDI, Inc. (Nasdaq: PDII) today announced that it has appointed molecular diagnostics industry veteran John M. Climaco, J.D., to its board of directors, bringing the board to seven members.
"As we continue to execute on our strategic vision of solidifying a position in the molecular diagnostics space, we welcome John's unparalleled business expertise in this market," said Nancy Lurker, chief executive officer of PDI, Inc. "John's role will be inv... |
|10/15/13||PDI, Inc. and Transgenomic, Inc. Partner to Commercialize Personalized Medicine Molecular Diagnostic Test|
|- Companies enter long-term collaboration advancing test designed for at-risk cardiac patients -
- PDI to host conference call today at 9:00AM ET -
PARSIPPANY, N.J. and OMAHA, Neb., Oct. 15, 2013 /PRNewswire/ -- PDI, Inc. (Nasdaq: PDII) and Transgenomic, Inc. (OTCBB: TBIO), today announced the signing of a U.S. collaboration agreement to commercialize CardioPredict™, a molecular diagnostic test developed by Transgenomic. CardioPredict™ is a broad-based genetic assay which identifies a pati... |